Linked Life Data

12074359

Source:http://linkedlifedata.com/resource/pubmed/id/12074359

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2002-6-20
pubmed:abstractText
The contribution of angiotensin-(1-7) [Ang-(1-7)] to the antihypertensive actions of omapatrilat, a novel vasopeptidase inhibitor, was evaluated in 22 salt-sensitive, low renin, hypertensive subjects as a substudy of a multicenter randomized, double-blind, parallel study of 4 weeks duration. A total of 25 other subjects received lisinopril as the active control. Omapatrilat (40 mg) produced sustained control of blood pressure (BP) (as assessed by 24-h ambulatory BP measurements) that was significantly greater than that produced by 20 mg daily of lisinopril. The antihypertensive response to either drug was accompanied by similar sustained inhibition of angiotensin converting enzyme activity. Plasma levels of angiotensin I (Ang I), angiotensin II (Ang II) and Ang-(1-7) were not altered by treatment with either omapatrilat or lisinopril, even though both regimens produced a modest rise in plasma renin activity. In contrast, urinary excretion rates of Ang I and Ang-(1-7) but not Ang II increased significantly throughout the dosing period of subjects who were given omapatrilat, whereas the smaller antihypertensive response produced by lisinopril had a smaller and transient effect on increasing urinary excretion rates of Ang-(1-7). Omapatrilat, being a single molecule inhibiting neutral endopeptidase and converting enzyme simultaneously, controlled salt-sensitive hypertension by a mechanism that was associated with sustained increases in urinary Ang-(1-7) excretion. We suggest that Ang-(1-7) may be a component of the mechanisms by which omapatrilat induces an antihypertensive response in salt sensitive hypertension.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0895-7061
pubmed:author
pubmed:issnType
Print
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
557-64
pubmed:dateRevised
2009-2-24
pubmed:meshHeading
pubmed-meshheading:12074359-Adolescent, pubmed-meshheading:12074359-Adult, pubmed-meshheading:12074359-Aged, pubmed-meshheading:12074359-Angiotensin-Converting Enzyme Inhibitors, pubmed-meshheading:12074359-Angiotensins, pubmed-meshheading:12074359-Atrial Natriuretic Factor, pubmed-meshheading:12074359-Blood Pressure Monitoring, Ambulatory, pubmed-meshheading:12074359-Double-Blind Method, pubmed-meshheading:12074359-Female, pubmed-meshheading:12074359-Humans, pubmed-meshheading:12074359-Hypertension, pubmed-meshheading:12074359-Lisinopril, pubmed-meshheading:12074359-Male, pubmed-meshheading:12074359-Middle Aged, pubmed-meshheading:12074359-Pyridines, pubmed-meshheading:12074359-Renin-Angiotensin System, pubmed-meshheading:12074359-Sodium, Dietary, pubmed-meshheading:12074359-Thiazepines, pubmed-meshheading:12074359-Treatment Outcome
pubmed:year
2002
pubmed:articleTitle
Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension.
pubmed:affiliation
Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. cferrari@wfubmc.edu
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study